Zobrazeno 1 - 10
of 29
pro vyhledávání: '"R Claramunt García"'
Publikováno v:
Late breaking abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8cc918a8d0ef8898e82ed357eabc1e42
https://doi.org/10.1136/ejhpharm-2023-eahp.361
https://doi.org/10.1136/ejhpharm-2023-eahp.361
Publikováno v:
Late breaking abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f4c35e688e82ddee437b1d54157ffcf
https://doi.org/10.1136/ejhpharm-2023-eahp.356
https://doi.org/10.1136/ejhpharm-2023-eahp.356
Autor:
R Claramunt García, CL Muñoz Cid, A Sánchez Ruiz, N Garcia Gomez, M Merino Almazán, T Sánchez Casanueva
Publikováno v:
Late breaking abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59840395d5539bec7d950c21e60e9f13
https://doi.org/10.1136/ejhpharm-2023-eahp.362
https://doi.org/10.1136/ejhpharm-2023-eahp.362
Autor:
T Sánchez Casanueva, R Claramunt García, N Garcia Gomez, TM Rodríguez Martínez, M Merino Almazán, V López Pozas, L Labián Román, S Vizcaíno Velázquez, MG Fanega Acosta, E Navarro Maestre
Publikováno v:
Late breaking abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6d94bbdf78d231df290c25030f97ecd
https://doi.org/10.1136/ejhpharm-2023-eahp.365
https://doi.org/10.1136/ejhpharm-2023-eahp.365
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac66e5f710f5db2e396b876cc150d74a
https://doi.org/10.1136/ejhpharm-2022-eahp.193
https://doi.org/10.1136/ejhpharm-2022-eahp.193
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50424696ea7a519ba63a38755612c398
https://doi.org/10.1136/ejhpharm-2022-eahp.73
https://doi.org/10.1136/ejhpharm-2022-eahp.73
Publikováno v:
Section 2: Selection, procurement and distribution.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0d50d9d0e5aefe5f4c2cd4d048e3172
https://doi.org/10.1136/ejhpharm-2022-eahp.19
https://doi.org/10.1136/ejhpharm-2022-eahp.19
Publikováno v:
Section 2: Selection, procurement and distribution.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a51ee5fed526aacebb389ed2fb0e609
https://doi.org/10.1136/ejhpharm-2022-eahp.20
https://doi.org/10.1136/ejhpharm-2022-eahp.20
Autor:
E Perez Cano, Y Jimenez López, CL Muñoz Cid, N Garcia Gomez, R Claramunt García, JF Marin Pozo
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Anti-PD-L1 immunotherapy is used to treat secondline or later non-small cell lung cancer (NSCLC). These monoclonal antibodies are the therapy of choice against NSCLC in routine clinical practice. Aim and objectives To evalua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3c71410b02ee95c63c0d84222393b98
https://doi.org/10.1136/ejhpharm-2021-eahpconf.103
https://doi.org/10.1136/ejhpharm-2021-eahpconf.103
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Apalutamide, enzalutamide and darolutamide have recently been approved for treating castration resistant non-metastatic prostate cancer (nmCRPC). The three drugs demonstrated efficacy over placebo in clinical trials, but the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7464f0d141e8251f9e1db00ae95dd7c7
https://doi.org/10.1136/ejhpharm-2021-eahpconf.139
https://doi.org/10.1136/ejhpharm-2021-eahpconf.139